Request Readiness Review

Submission requirements

See what a reviewer will ask you for.

Pick your product category and target region. This is the evidence structure DSRV works from, section by section, with the regulation or guidance behind every line. No account, no upload, no readiness grade.

Product category

Submission region

Tablets (oral solid dose) · China (NMPA / ChP)

11 sections · 53 evidence items

Citations are regulatory anchors for orientation, not an exhaustive or binding checklist. DSRV's reviewer confirms applicability to your specific product and submission type.

  1. Section 01

    Product Overview

    • NMPADrug Registration Regulation (2020) — registration category context

    • Product profile (name, dosage form, strengths)

    • Market / region target

    • Submission type

    • Client owner / contact

  2. Section 02

    Raw Materials & Components

    • ChPChinese Pharmacopoeia applicable monographs

    • API information

    • Excipients

    • Packaging components

    • Supplier / vendor documents

    • Certificates of analysis

    • Material specifications

  3. Section 03

    Manufacturing Process

    • CN GMPChina GMP (2010 revision) — production management

    • Process description

    • Master production / control record references

    • Manufacturing flow

    • Critical process parameters

    • Equipment / process notes

    • In-process controls

  4. Section 04

    Specifications & Methods

    • ChPChP Volume IV general chapters; NMPA technical guidelines

    • Finished product specifications

    • Raw material specifications

    • Analytical methods

    • Method validation / verification documents

    • Acceptance criteria

  5. Section 05

    Batch Records

    • CN GMPChina GMP — batch production records

    • Executed batch records

    • Master batch record

    • Deviations / investigations

    • Batch disposition / release records

  6. Section 06

    Validation & Verification

    • CN GMPChina GMP Annexes — validation

    • Process validation

    • Cleaning validation (if applicable)

    • Method validation / verification

    • Equipment qualification references

    • Continued process verification

  7. Section 07

    Test Results & Quality Data

    • NMPACTD-format batch analyses (NMPA 2020 alignment)

    • Finished product test results

    • Raw material test results

    • In-process test results

    • OOS / OOT investigations

    • Data tables / structured result uploads

  8. Section 08

    Stability & Shelf-Life Evidence

    • NMPANMPA stability guideline (ICH Q1A-aligned)

    • Stability protocol

    • Stability pulls / intervals

    • Stability results

    • Trend summaries

    • Shelf-life justification

  9. Section 09

    Safety / Suitability / Risk Evidence

    • ICHICH Q9 (NMPA member adoption)

    • Quality risk assessment

    • Impurity / degradation risk

    • Safety support documents

    • Product quality rationale

  10. Section 10

    Labeling & Packaging Evidence

    • NMPADrug instruction/label administration provisions

    • Label copy

    • Packaging specifications

    • Artwork / control records

    • Packaging batch evidence

  11. Section 11

    Submission Readiness Review

    • DSRVDSRV submission-readiness review gate

    • Completeness checklist

    • Missing items

    • Reviewer comments

    • Client action items

    • Readiness status

What happens next

Nothing here needs a document from you

This list is the starting structure, not a verdict on your programme. Evidence only moves into a private, engagement-scoped workspace after confidentiality scope is agreed, and a DSRV reviewer confirms which items actually apply to your product.